BYAM REBECCA (Chief Financial Officer) purchased 1.8% of their position (10K shares) of HCW BIOLOGICS INC. on the open market
Open‑market purchase worth $19.9K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 9/8/2023ACC: 0001209191-23-048824
Officer· Chief Financial Officer
Since Jul 2021
+10K
Net shares
Net buyer
$19.9K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
10K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5K
Price / share
$1.95
Trade value
$9.74K
% of position
0.9%
9/7/2023
548.95K→553.95K
Common Stock
Direct
Shares
+5K
Price / share
$2.02
Trade value
$10.11K
% of position
0.9%
9/8/2023
553.95K→558.95K
Total
Net shares
+10K
Net value
$19.85K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/7/2023 | P · Purchase | +5K | $1.95 | $9.74K | 0.9% | 548.95K | 553.95K |
| Common Stock Direct | 9/8/2023 | P · Purchase | +5K | $2.02 | $10.11K | 0.9% | 553.95K | 558.95K |
| Total | +10K | $19.85K | ||||||
Derivative Transactions0
No derivative transactions reported